Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.
BACKGROUND: Robot-assisted radical prostatectomy (RARP) is an increasingly commonly used surgical treatment option for prostate cancer (PCa); however, its longer-term oncologic results remain uncertain. OBJECTIVE: To report biochemical recurrence-free survival (BRFS) outcomes for men who underwent...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797082342377914368 |
|---|---|
| author | Sooriakumaran, P Haendler, L Nyberg, T Gronberg, H Nilsson, A Carlsson, S Hosseini, A Adding, C Jonsson, M Ploumidis, A Egevad, L Steineck, G Wiklund, P |
| author_facet | Sooriakumaran, P Haendler, L Nyberg, T Gronberg, H Nilsson, A Carlsson, S Hosseini, A Adding, C Jonsson, M Ploumidis, A Egevad, L Steineck, G Wiklund, P |
| author_sort | Sooriakumaran, P |
| collection | OXFORD |
| description | BACKGROUND: Robot-assisted radical prostatectomy (RARP) is an increasingly commonly used surgical treatment option for prostate cancer (PCa); however, its longer-term oncologic results remain uncertain. OBJECTIVE: To report biochemical recurrence-free survival (BRFS) outcomes for men who underwent RARP ≥5 yr ago at a single European centre. DESIGN, SETTING, AND PARTICIPANTS: A total of 944 patients underwent RARP as monotherapy for PCa from January 2002 to December 2006 at Karolinska University Hospital, Stockholm, Sweden. Standard clinicopathologic variables were recorded and entered into a secure, ethics-approved database made up of those men with registered domiciles in Stockholm. The median follow-up time was 6.3 yr (interquartile range: 5.6-7.2). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome of this study was biochemical recurrence (BCR), defined as a confirmed prostate-specific antigen (PSA) of ≥0.2 ng/ml. Kaplan-Meier survival plots with log-rank tests, as well as Cox univariable and multivariable regression analyses, were used to determine BRFS estimates and determine predictors of PSA relapse, respectively. RESULTS AND LIMITATIONS: The BRFS for the entire cohort at median follow-up was 84.8% (95% confidence interval [CI], 82.2-87.1); estimates at 5, 7, and 9 yr were 87.1% (95% CI, 84.8-89.2), 84.5% (95% CI, 81.8-86.8), and 82.6% (95% CI, 79.0-85.6), respectively. Nine and 19 patients died of PCa and other causes, respectively, giving end-of-follow-up Kaplan-Meier survival estimates of 98.0% (95% CI, 95.5-99.1) and 94.1% (95% CI, 90.4-96.4), respectively. Preoperative PSA >10, postoperative Gleason sum ≥4 + 3, pathologic T3 disease, positive surgical margin status, and lower surgeon volume were associated with increased risk of BCR on multivariable analysis. This study is limited by a lack of nodal status and tumour volume, which may have confounded our findings. CONCLUSIONS: This case series from a single, high-volume, European centre demonstrates that RARP has satisfactory medium-term BRFS. Further follow-up is necessary to determine how this finding will translate into cancer-specific and overall survival outcomes. |
| first_indexed | 2024-03-07T01:26:49Z |
| format | Journal article |
| id | oxford-uuid:9244464f-f5f8-485a-ad43-a584d18fa20a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:26:49Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:9244464f-f5f8-485a-ad43-a584d18fa20a2022-03-26T23:24:15ZBiochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9244464f-f5f8-485a-ad43-a584d18fa20aEnglishSymplectic Elements at Oxford2012Sooriakumaran, PHaendler, LNyberg, TGronberg, HNilsson, ACarlsson, SHosseini, AAdding, CJonsson, MPloumidis, AEgevad, LSteineck, GWiklund, P BACKGROUND: Robot-assisted radical prostatectomy (RARP) is an increasingly commonly used surgical treatment option for prostate cancer (PCa); however, its longer-term oncologic results remain uncertain. OBJECTIVE: To report biochemical recurrence-free survival (BRFS) outcomes for men who underwent RARP ≥5 yr ago at a single European centre. DESIGN, SETTING, AND PARTICIPANTS: A total of 944 patients underwent RARP as monotherapy for PCa from January 2002 to December 2006 at Karolinska University Hospital, Stockholm, Sweden. Standard clinicopathologic variables were recorded and entered into a secure, ethics-approved database made up of those men with registered domiciles in Stockholm. The median follow-up time was 6.3 yr (interquartile range: 5.6-7.2). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcome of this study was biochemical recurrence (BCR), defined as a confirmed prostate-specific antigen (PSA) of ≥0.2 ng/ml. Kaplan-Meier survival plots with log-rank tests, as well as Cox univariable and multivariable regression analyses, were used to determine BRFS estimates and determine predictors of PSA relapse, respectively. RESULTS AND LIMITATIONS: The BRFS for the entire cohort at median follow-up was 84.8% (95% confidence interval [CI], 82.2-87.1); estimates at 5, 7, and 9 yr were 87.1% (95% CI, 84.8-89.2), 84.5% (95% CI, 81.8-86.8), and 82.6% (95% CI, 79.0-85.6), respectively. Nine and 19 patients died of PCa and other causes, respectively, giving end-of-follow-up Kaplan-Meier survival estimates of 98.0% (95% CI, 95.5-99.1) and 94.1% (95% CI, 90.4-96.4), respectively. Preoperative PSA >10, postoperative Gleason sum ≥4 + 3, pathologic T3 disease, positive surgical margin status, and lower surgeon volume were associated with increased risk of BCR on multivariable analysis. This study is limited by a lack of nodal status and tumour volume, which may have confounded our findings. CONCLUSIONS: This case series from a single, high-volume, European centre demonstrates that RARP has satisfactory medium-term BRFS. Further follow-up is necessary to determine how this finding will translate into cancer-specific and overall survival outcomes. |
| spellingShingle | Sooriakumaran, P Haendler, L Nyberg, T Gronberg, H Nilsson, A Carlsson, S Hosseini, A Adding, C Jonsson, M Ploumidis, A Egevad, L Steineck, G Wiklund, P Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. |
| title | Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. |
| title_full | Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. |
| title_fullStr | Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. |
| title_full_unstemmed | Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. |
| title_short | Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years. |
| title_sort | biochemical recurrence after robot assisted radical prostatectomy in a european single centre cohort with a minimum follow up time of 5 years |
| work_keys_str_mv | AT sooriakumaranp biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT haendlerl biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT nybergt biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT gronbergh biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT nilssona biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT carlssons biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT hosseinia biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT addingc biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT jonssonm biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT ploumidisa biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT egevadl biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT steineckg biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years AT wiklundp biochemicalrecurrenceafterrobotassistedradicalprostatectomyinaeuropeansinglecentrecohortwithaminimumfollowuptimeof5years |